Skip to search formSkip to main contentSkip to account menu

BBR 3576

Known as: BBR-3576, BBR3576 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Heterocyclic Compounds, 4 or More RingsPyrazoles
Topixantrone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central…
BBR 3576 is a novel aza-anthrapyrazole with limited potential for cardiotoxicity in preclinical models. This phase I clinical and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)